Kenvue Inc. $KVUE Shares Sold by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd lowered its position in Kenvue Inc. (NYSE:KVUE) by 56.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 835,425 shares of the company’s stock after selling 1,103,432 shares during the period. UniSuper Management Pty Ltd’s holdings in Kenvue were worth $13,559,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Renaissance Capital LLC increased its holdings in Kenvue by 8.3% during the 2nd quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock valued at $13,169,000 after acquiring an additional 48,267 shares in the last quarter. Cornell Pochily Investment Advisors Inc. grew its holdings in Kenvue by 144.6% during the 2nd quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock valued at $694,000 after buying an additional 19,609 shares during the last quarter. TrueMark Investments LLC lifted its position in shares of Kenvue by 8.8% in the second quarter. TrueMark Investments LLC now owns 229,648 shares of the company’s stock valued at $4,807,000 after acquiring an additional 18,623 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Kenvue by 1.8% during the second quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock valued at $4,881,844,000 after acquiring an additional 4,101,880 shares during the last quarter. Finally, OFI Invest Asset Management increased its position in Kenvue by 705.6% during the 2nd quarter. OFI Invest Asset Management now owns 26,979 shares of the company’s stock worth $565,000 after purchasing an additional 23,630 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Up 0.4%

Shares of NYSE KVUE opened at $17.82 on Friday. The company has a market cap of $34.14 billion, a P/E ratio of 23.76 and a beta of 0.60. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $25.17. The stock has a fifty day moving average price of $17.05 and a 200 day moving average price of $18.15.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.Kenvue’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.7%. The ex-dividend date of this dividend was Wednesday, November 12th. Kenvue’s payout ratio is presently 110.67%.

Insider Transactions at Kenvue

In other Kenvue news, Director Jeffrey C. Smith bought 3,200,000 shares of the business’s stock in a transaction on Friday, December 12th. The shares were bought at an average cost of $17.37 per share, with a total value of $55,584,000.00. Following the transaction, the director directly owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. This trade represents a 13.27% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.68% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on KVUE. Evercore ISI set a $18.00 target price on shares of Kenvue in a report on Tuesday, October 28th. UBS Group reduced their target price on Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a report on Friday, January 9th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $15.00 price objective (down previously from $26.00) on shares of Kenvue in a research note on Wednesday, October 29th. Finally, Edward Jones lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $20.23.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.